Key result
Tenascin-C was an independent predictor of mortality in patients with dilated cardiomyopathy and its decrease correlated with reverse remodeling.
Why the study?
Does tenascin-C predict left ventricular reverse remodeling and mortality in patients with dilated cardiomyopathy?
Observational (n=66)
Does tenascin-C predict left ventricular reverse remodeling and mortality in patients with dilated cardiomyopathy?
Tenascin-C is a useful biomarker for predicting mortality and evaluating reverse left ventricular remodeling in patients with dilated cardiomyopathy on guideline-directed medical therapy.
Answers are grounded in this paper and cite their sources.
Tenascin-C may support prognostic stratification in dilated cardiomyopathy; leaves open its incremental value over established markers.
BACKGROUND: Several cardiac biomarkers, especially brain natriuretic peptide (BNP) and N-terminal (NT)-proBNP, have been used as predictors of prognosis and negative remodeling in DCM. In the present study, we aimed to evaluate the prognostic value of tenascin-C in dilated cardiomyopathy (DCM) and whether it can be used to determine reverse remodeling in patients with DCM. METHODS: Sixty-six patients with DCM were followed up for 12 months after initiation of medical treatment including carvedilol, ramipril (candesartan if ramipril was not tolerated), spironolactone, and furosemide. Tenascin-C and NT-proBNP measurements and transthoracic echocardiography were performed at baseline and at 12 months. RESULTS: At 12 months, a significant improvement in New York Heart Association class (2.57 ± 0.6 vs. 1.87 ± 0.5; P < 0.0001), left ventricular end-diastolic volume (217 ± 47 vs 203 ± 48; P < 0.0001), left ventricular ejection fraction (29.1 ± 5.5 vs 30.9 ± 3.8; P < 0.0001), NT-proBNP (2019 ± 558 vs 1462 ± 805; P < 0.0001), and tenascin-C (76 ± 19 vs 48 ± 28; P < 0.0001) values were observed, compared with baseline. Importantly, decrease in tenascin-C values were correlated with increase in left ventricular ejection fraction. Tenascin-C (odds ratio [OR], 1.896; <95% confidence interval [CI], 1.543-2.670; P = 0.02), diabetes mellitus (OR, 2.456; G95% CI, 1.987-3.234; P = 0.01) and hypertension (OR: 2.106, <95% CI, 1.876-2.897; P = 0.03) were independent predictors of mortality in patients with DCM. CONCLUSION: Reverse ventricular remodeling obtained with carvedilol, ramipril/candesartan, and spironolacton is associated with decreases in left ventricular end-diastolic volume, left ventricular end-systolic volume, tenascin-C levels, and NT-proBNP levels. Consequently, tenascin-C may be used to evaluate reverse remodeling in patients with DCM.
No takes yet. Share an insight, caveat, or question.
Şarlı et al. (2013) conducted an observational in Dilated cardiomyopathy (DCM) (n=66). Tenascin-C levels was evaluated on Mortality (OR 1.896, 95% CI 1.543-2.670, p=0.02). Tenascin-C was an independent predictor of mortality in patients with dilated cardiomyopathy and its decrease correlated with reverse remodeling.
Synapse has enriched 10 related papers. Consider them for comparative context: